A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)
Year: 2019
Type: article
Authors: Ehab Atallah, Mark Berger, Joseph Jurcic, Gail Roboz, William Tse, Raya Mawad, David Rizzieri, Kebede Begna, Johnnie Orozco, Michael Craig, Moshe Yair Levy, Laura Finn, Khan Sharif, Alexander Perl, Jae Park
Institutions: Medical College of Wisconsin, Actinium Pharmaceuticals (United States), Columbia University Irving Medical Center, Cornell University, Weill Cornell Medicine, University of Louisville, Duke University, Mayo Clinic, Fred Hutch Cancer Center, West Virginia University, Baylor University Medical Center, Ochsner Medical Center, University of Pennsylvania, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4243123473